TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$258.75 Million

ATAI Life Sciences B.V.

Initial Public Offering

Bookrunner, June 2021

ATAI Life Sciences B.V.

ATAI Life Sciences B.V. (the “Company”) is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. The Company was formed as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics. The Company has built a pipeline of 10 development programs and six enabling technologies.